Journal of Drug Discovery and Health Sciences

Review Article

Advances in Computational Chemistry for Drug Discovery

Shailesh Pathak[1], Shom P. Kushwaha[2], Shikhar Verma[3], Prakash Deep[3], Deepika Gupta[3*]

[1]Department of Pharmaceutical Chemistry, Shambhunath Institute of Pharmacy, Prayagraj, Uttar Pradesh, India.
[2]Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India.
[3]Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, Uttar Pradesh, India.

ARTICLE INFO

ABSTRACT

The integration of computational chemistry into drug discovery has significantly enhanced the efficiency and precision of developing new therapeutics. This review provides a comprehensive overview of the evolution and key techniques in computational chemistry, including molecular docking, molecular dynamics simulations, quantum mechanics/molecular mechanics (QM/MM) methods, pharmacophore modeling, and quantitative structure-activity relationship (QSAR) modeling. The application of these techniques in virtual screening, lead optimization, drug-target interaction predictions, and drug repurposing is discussed, highlighting their impact on the drug discovery process. The review also explores the role of artificial intelligence (AI) and machine learning (ML) in advancing predictive modeling and accelerating drug design, emphasizing the challenges associated with computational costs, prediction accuracy, data quality, and ethical considerations. Furthermore, emerging trends in the field, such as quantum computing, personalized medicine, and the integration of computational methods with experimental techniques, are examined. The importance of open science and collaborative platforms in democratizing drug discovery is also addressed. In conclusion, while computational chemistry has already revolutionized drug discovery, ongoing advancements in technology and methodology promise to further transform the field, enabling more targeted and efficient therapeutic development.

INTRODUCTION

The drug discovery process is a complex and multifaceted endeavor, traditionally relying heavily on experimental techniques to identify and optimize potential therapeutic agents. This process, which includes target identification, lead compound discovery, and clinical trials, is both time-consuming and expensive, often taking years and billions of dollars to bring a new drug to market (Hughes *et al.*, 2011). With the advent of computational chemistry, however, there has been a significant transformation in how drugs are discovered and developed. Computational chemistry employs theoretical and computational methods to simulate the behavior of molecules and predict their interactions, thereby streamlining various stages of drug discovery and reducing the need for extensive experimental testing (Jorgensen, 2009).

The field of computational chemistry has evolved rapidly over the past few decades, driven by advancements in computer technology and the development of sophisticated algorithms. Early milestones in this field include the development of molecular mechanics and quantum chemistry methods, which allowed for the simulation of molecular structures and interactions at an unprecedented level of detail (Karplus & McCammon, 2002). These

*Corresponding Author: Deepika Gupta

Address: Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, Uttar Pradesh, India.

Email ✉: deepika26009@gmail.com

techniques have since been refined and expanded to include molecular dynamics simulations, molecular docking, and hybrid quantum mechanics/molecular mechanics (QM/MM) approaches, all of which play a critical role in modern drug discovery (Sliwoski *et al.*, 2014).

Computational chemistry has become an integral component of drug discovery, offering tools that enable researchers to virtually screen large libraries of compounds, predict the binding affinity of drug candidates to their targets, and optimize lead compounds for better efficacy and reduced toxicity (Shoichet, 2004). As a result, pharmaceutical companies and research institutions increasingly rely on these methods to accelerate the drug development process and improve the success rate of new therapeutic agents.

Given the rapid evolution and the increasing importance of computational chemistry in drug discovery, this review aims to explore the key techniques and recent advances in this field. We will discuss the application of molecular docking, molecular dynamics, QM/MM methods, pharmacophore modeling, and quantitative structure-activity relationship (QSAR) analysis in drug discovery. Additionally, we will examine the integration of artificial intelligence and machine learning with computational chemistry, highlighting their transformative impact on the field. Finally, the review will address the challenges and limitations of current computational approaches and suggest future directions for research and development.

Techniques In Computational Chemistry

Molecular Docking

Molecular docking is a cornerstone technique in computational drug discovery, designed to predict the preferred orientation of a small molecule (ligand) when bound to a target protein. The purpose of molecular docking is to estimate the binding affinity between the ligand and the protein, which is critical for understanding the potential efficacy of a drug candidate (Meng *et al.*, 2011). Various algorithms and methods have been developed to enhance the accuracy and efficiency of molecular docking. Among the most widely used are the rigid-body docking approaches, which consider the protein and ligand as fixed entities, and flexible docking methods that allow for conformational changes in the ligand or protein during the docking process (Morris & Lim-Wilby, 2008). Docking tools such as AutoDock, Glide, and DOCK have been extensively used in virtual screening campaigns, enabling the rapid assessment of large compound libraries to identify promising leads (Kitchen *et al.*, 2004).

Molecular Dynamics Simulations

Molecular dynamics (MD) simulations are a powerful computational tool used to study the dynamic behavior of biomolecules at an atomic level. These simulations provide insights into the conformational changes and interactions of molecules over time, offering a deeper understanding of drug-receptor interactions (Karplus & Kuriyan, 2005). MD simulations can be categorized into various types, including all-atom simulations, which provide detailed information about every atom in the system, and coarse-grained simulations, which simplify the system by grouping atoms into larger units to reduce computational costs (Klepeis *et al.*, 2009). The role of MD simulations in drug discovery is particularly significant in studying the flexibility of proteins and ligands, predicting the stability of drug-receptor complexes, and exploring the thermodynamics and kinetics of binding processes (Dror *et al.*, 2012).

Quantum Mechanics/Molecular Mechanics (QM/MM)

Quantum Mechanics/Molecular Mechanics (QM/MM) is a hybrid computational technique that combines the accuracy of quantum mechanics (QM) with the efficiency of molecular mechanics (MM). In QM/MM, the region of interest, such as the active site of an enzyme, is treated using quantum mechanics, while the surrounding environment is modeled using classical molecular mechanics (Senn & Thiel, 2009). This approach allows for the accurate simulation of chemical reactions within biological systems while maintaining computational feasibility. QM/MM methods are particularly useful in drug design and optimization, as they enable the detailed study of reaction mechanisms, the calculation of activation energies, and the prediction of binding affinities with a higher degree of accuracy than MM methods alone (Lin & Truhlar, 2007).

Pharmacophore Modeling

Pharmacophore modeling is a key technique in drug discovery that involves the identification of the essential features of a molecule responsible for its biological activity. A pharmacophore is defined as an abstract representation of the molecular features necessary for the optimal interaction with a specific biological target, leading to the desired pharmacological effect (Schuster *et al.*, 2006). The process of pharmacophore model generation typically involves the alignment of active compounds to identify common features, followed by the validation and refinement of the model using a training set of known active and inactive compounds (Leach *et al.*, 2010). Pharmacophore models are widely used in virtual screening to identify novel compounds that share the same key features, even if they have different chemical structures (Yang, 2010).

Quantitative Structure-Activity Relationship (QSAR)

Quantitative Structure-Activity Relationship (QSAR) is a computational technique that correlates the chemical structure of compounds with their biological activity through mathematical models. QSAR models can be categorized into different types, including 2D-QSAR, which

J. Drug Disc. Health Sci., July - September, 2024, Vol 1, Issue 3, 146-152

147

relies on two-dimensional descriptors, and 3D-QSAR, which incorporates three-dimensional properties of molecules (Patel *et al.*, 2014). The primary goal of QSAR is to predict the activity or toxicity of new compounds based on their structural properties, making it a valuable tool in the early stages of drug discovery (Cherkasov *et al.*, 2014). By identifying key structural features that contribute to biological activity, QSAR models can guide the design and optimization of more potent and selective drug candidates (Verma *et al.*, 2010).

Applications of Computational Chemistry in Drug Discovery (Table 1)

Virtual Screening

Virtual screening is a critical application of computational chemistry, enabling the rapid identification of potential drug candidates from vast chemical libraries. High-throughput virtual screening (HTVS) involves the automated testing of millions of compounds against biological targets to identify those with the highest likelihood of binding effectively (Langer & Hoffmann, 2010). HTVS uses molecular docking techniques to simulate the interaction between the target protein and various ligands, ranking them based on predicted binding affinity (Lionta *et al.*, 2014). This process significantly reduces the time and cost associated with experimental screening methods. Successful applications of HTVS include the identification of novel inhibitors for enzymes like HIV-1 protease and HMG-CoA reductase, where virtual screening identified potent candidates that were later validated experimentally (Gaba *et al.*, 2014).

Lead Optimization

Once potential drug candidates are identified through virtual screening or other methods, the next step is lead optimization. This process involves refining the chemical structure of the lead compounds to improve their efficacy, selectivity, and pharmacokinetic properties while minimizing toxicity (Hughes *et al.*, 2011). Computational tools play a pivotal role in this stage by predicting the effects of chemical modifications on the biological activity of the lead compounds. Techniques such as molecular dynamics simulations, free energy perturbation (FEP), and quantitative structure-activity relationship (QSAR) models are commonly employed to optimize the binding affinity and selectivity of the leads (Shen *et al.*, 2014). For instance, the optimization of kinase inhibitors, which are crucial in cancer treatment, has been greatly accelerated by computational methods that predict how changes in the molecular structure affect the interaction with kinase targets (Zhang *et al.*, 2015).

Drug-Target Interaction Predictions

Accurate prediction of drug-target interactions is fundamental to successful drug design. Computational chemistry provides a suite of tools for this purpose, ranging from molecular docking and molecular dynamics simulations to more advanced techniques like homology modeling and quantum mechanics/molecular mechanics (QM/MM) methods (Lavecchia & Di Giovanni, 2013). These tools allow researchers to predict how well a drug candidate will bind to its target and understand the molecular basis of the interaction, which is critical for optimizing drug efficacy and reducing off-target effects. For example, the development of G protein-coupled receptor (GPCR) modulators has greatly benefited from computational predictions of drug-target interactions, leading to the discovery of new therapeutic agents for diseases such as hypertension and schizophrenia (Kooistra *et al.*, 2015).

Drug Repurposing

Drug repurposing, or repositioning, involves finding new therapeutic uses for existing drugs, and computational chemistry has become an invaluable tool in this endeavor. By leveraging virtual screening and drug-target interaction predictions, researchers can identify off-target effects of known drugs that may be therapeutically beneficial for other conditions (Ashburn & Thor, 2004). Computational methods have been instrumental in repurposing drugs like thalidomide for multiple myeloma and sildenafil for

Table 1: Summary of Key Applications of Computational Chemistry in Drug Discovery

Application	Description	Examples	References
Virtual Screening	Rapid identification of potential drug candidates from large chemical libraries using automated testing.	Identified inhibitors for HIV-1 protease and HMG-CoA reductase.	Langer & Hoffmann (2010); Lionta *et al.* (2014); Gaba *et al.* (2014)
Lead Optimization	Refining chemical structures of lead compounds to improve efficacy, selectivity, and pharmacokinetics.	Optimized kinase inhibitors for cancer treatment.	Hughes *et al.* (2011); Shen *et al.* (2014); Zhang *et al.* (2015)
Drug-Target Interaction	Prediction of drug binding to biological targets using molecular docking, dynamics, and QM/MM methods.	Development of GPCR modulators for hypertension and schizophrenia.	Lavecchia & Di Giovanni (2013); Kooistra *et al.* (2015)
Drug Repurposing	Finding new therapeutic uses for existing drugs through computational screening and interaction predictions.	Repurposed thalidomide for multiple myeloma; sildenafil for hypertension.	Ashburn & Thor (2004); Nosengo (2016); Sultana *et al.* (2020)

pulmonary hypertension (Nosengo, 2016). Additionally, during the COVID-19 pandemic, computational approaches were used to screen existing antiviral drugs for efficacy against SARS-CoV-2, leading to the rapid identification of candidates for clinical trials (Sultana *et al.*, 2020).

Integration of AI and Machine Learning in Computational Chemistry

Artificial intelligence (AI) and machine learning (ML) are increasingly being integrated into computational chemistry, revolutionizing the drug discovery process. AI encompasses a broad range of technologies that enable machines to mimic human intelligence, while ML, a subset of AI, focuses on developing algorithms that allow computers to learn from and make predictions based on data (LeCun, Bengio, & Hinton, 2015). In drug discovery, AI/ML techniques are employed to analyze vast amounts of data, identify patterns, and generate predictive models that can significantly accelerate the identification and optimization of drug candidates (Chen *et al.*, 2018). Key AI/ML approaches used in computational chemistry include supervised learning, unsupervised learning, and reinforcement learning, each playing a unique role in different stages of the drug development pipeline (Ekins *et al.*, 2019).

AI-Driven Drug Design

AI-driven drug design represents a significant advancement in the field of computational chemistry, offering unprecedented speed and accuracy in identifying potential drug candidates. AI techniques, such as deep learning and generative models, can rapidly analyze chemical space and predict the properties of new molecules, allowing for the design of novel compounds with desired biological activities (Zhavoronkov *et al.*, 2019). For example, Insilico Medicine used an AI-driven approach to design and synthesize a novel inhibitor for a target protein implicated in fibrosis, completing the entire process in just 46 days—a timeline significantly shorter than traditional drug discovery methods (Zhavoronkov *et al.*, 2019). AI has also been successfully applied in optimizing existing compounds, leading to the development of more potent and selective drug candidates (Ramsundar *et al.*, 2015).

Predictive Modeling

Predictive modeling is a crucial aspect of drug discovery, where AI/ML plays a vital role in enhancing the accuracy and reliability of these models. Traditional quantitative structure-activity relationship (QSAR) models, which predict the biological activity of compounds based on their chemical structure, have been significantly improved by incorporating AI/ML techniques (Cherkasov *et al.*, 2014). AI-assisted QSAR models use deep learning algorithms to capture complex, non-linear relationships between molecular descriptors and biological activity, resulting in more accurate predictions (Xu *et al.*, 2017). For instance,

Google's DeepChem platform has demonstrated the ability to predict molecular properties with high accuracy, facilitating the discovery of new drug candidates (Wu *et al.*, 2018). AI/ML models are also increasingly being used to predict drug-target interactions, toxicity, and pharmacokinetic properties, further streamlining the drug discovery process (Tang *et al.*, 2018).

While the integration of AI and ML in computational chemistry holds great promise, several challenges must be addressed to fully realize its potential. One of the primary challenges is the integration of AI with existing computational methods, such as molecular docking and molecular dynamics simulations, which require the development of hybrid approaches that can seamlessly combine different techniques (Coley *et al.*, 2019). Additionally, the quality and availability of data used to train AI/ML models are critical, as biased or incomplete data can lead to inaccurate predictions (Bender & Cortés-Ciriano, 2021). Future research should focus on developing more robust, interpretable AI models and improving data-sharing practices to enhance the reliability and transparency of AI-driven drug discovery (Jumper *et al.*, 2021). Despite these challenges, the future of AI in computational chemistry is bright, with the potential to transform the drug discovery landscape by enabling faster, more efficient, and more accurate identification of therapeutic agents.

Challenges and Limitations of Computational Chemistry

Computational chemistry faces several key challenges, including high computational costs, accuracy of predictions, data quality, and ethical and regulatory concerns (Table 2). Advanced methods like quantum mechanics and molecular dynamics require substantial computational resources, often limiting their accessibility and slowing research progress. Accuracy issues arise from the limitations of classical force fields and the impracticality of quantum methods for large systems. Additionally, the effectiveness of computational models is heavily dependent on the quality and completeness of input data, which can be inconsistent or incomplete. Ethical and regulatory concerns also arise, particularly with AI-driven models, which can lack transparency and face stringent validation requirements from regulatory agencies. These factors collectively impact the efficiency and adoption of computational chemistry in research and drug discovery.

Future Trends in Computational Chemistry for Drug Discovery

The landscape of computational chemistry is rapidly evolving with significant advances in computational hardware and algorithm development. Quantum computing, for instance, holds the potential to revolutionize drug discovery by providing unprecedented computational power to solve complex quantum mechanical problems

Table 2: Challenges and Limitations in Computational Chemistry

Challenge	Description	Impact	References
Computational Costs	High computational power required for complex simulations and modeling.	Limited access to resources; long processing times can slow research.	De Vivo *et al.* (2016); Lauterbach *et al.* (2020); Guimaraes *et al.* (2021)
Accuracy of Predictions	Accuracy depends on computational methods and models; errors can arise from classical force fields or QM methods.	Potential for inaccurate predictions affecting drug development and research outcomes.	Wang *et al.* (2017); Lonsdale *et al.* (2012)
Data Quality and Availability	Quality and completeness of input data affect model outcomes; challenges in data management and preprocessing.	Inconsistent or noisy data can lead to inaccurate predictions and model performance issues.	Sliwoski *et al.* (2014); Bottaro *et al.* (2018); Lee *et al.* (2019)
Ethical and Regulatory Considerations	Transparency and interpretability of AI models; regulatory scrutiny for AI-driven methods.	Ethical dilemmas and regulatory challenges can impede the adoption and validation of new technologies.	Vayena *et al.* (2018); Topol (2019)

that are currently intractable with classical computers (Arute *et al.*, 2019). Quantum computers could potentially simulate molecular interactions with high precision, thus accelerating the discovery of novel drug candidates. Concurrently, new algorithms and methods are being developed to enhance the efficiency and accuracy of simulations. For example, advances in machine learning techniques are enabling the development of more sophisticated predictive models and optimization algorithms, which can significantly streamline the drug discovery process (Riley *et al.*, 2022).

Personalized Medicine

Computational chemistry is increasingly playing a crucial role in the advancement of personalized medicine. By leveraging detailed patient data, computational models can help design tailored drug treatments that are more effective and have fewer side effects. Techniques such as molecular docking and dynamics simulations are used to predict how individual patients will respond to specific drugs based on their unique genetic and biochemical profiles (Wang *et al.*, 2020). This personalized approach not only enhances treatment efficacy but also minimizes adverse reactions, thus marking a significant shift towards more individualized therapeutic strategies.

Integration with Experimental Techniques

The synergy between computational and experimental techniques is becoming a cornerstone of modern drug discovery. Integrated workflows that combine computational predictions with experimental validation are increasingly common, allowing for more comprehensive and reliable drug development processes. For example, computational models can guide the design of experimental assays, while experimental data can be used to refine and validate computational predictions (Gavezzotti *et al.*, 2021). This integration enhances the overall efficiency of drug discovery and ensures that computational models are grounded in empirical data, thus bridging the gap between theoretical predictions and practical applications.

Open Science and Collaborative Platforms

The rise of open science and collaborative platforms is transforming the field of drug discovery by promoting transparency and accessibility. Open-source tools and databases, such as the Protein Data Bank (PDB) and various computational chemistry software, are enabling researchers worldwide to access and contribute to a shared pool of resources (Berman *et al.*, 2000). These collaborative platforms facilitate the democratization of drug discovery, allowing researchers from diverse backgrounds and institutions to collaborate effectively and share data and insights. This trend is fostering a more inclusive and accelerated drug discovery process, as researchers can build upon each other's work and leverage collective expertise (Nielsen, 2012).

Discussion

Computational chemistry has seen significant advancements in recent years, driven by emerging technologies, personalized medicine, and improved integration with experimental techniques. Quantum computing, for instance, holds promise for revolutionizing drug discovery by offering unprecedented computational power to solve complex molecular problems that are currently beyond the reach of classical computers (Arute *et al.*, 2019). This technological leap could enable more precise simulations of molecular interactions, potentially accelerating the identification of new drug candidates. Additionally, advances in machine learning are enhancing predictive modeling and optimization algorithms, further streamlining drug discovery processes (Riley *et al.*, 2022). Personalized medicine represents another significant trend, with computational chemistry playing a pivotal role in tailoring drug treatments to individual patients. By integrating detailed patient data into computational models, researchers can predict individual responses to drugs more accurately, thereby optimizing treatment efficacy and minimizing adverse effects (Wang *et al.*, 2020). This approach signifies a shift towards more

individualized therapeutic strategies, reflecting a growing emphasis on personalized healthcare.

The integration of computational methods with experimental techniques is also increasingly important in drug discovery. Combining computational predictions with empirical data facilitates a more comprehensive drug development process. Computational models can guide experimental design, while experimental results can validate and refine these models, thus enhancing the overall efficiency of drug discovery (Gavezzotti *et al.*, 2021).

Furthermore, the rise of open science and collaborative platforms is transforming the field by promoting transparency and accessibility. Open-source tools and databases, such as the Protein Data Bank, enable researchers globally to access and contribute to a shared repository of resources, fostering collaboration and accelerating drug discovery efforts (Berman *et al.*, 2000). This collaborative approach helps democratize research and leverages collective expertise, making the drug discovery process more inclusive and efficient.

Despite these advancements, computational chemistry still faces challenges, including high computational costs, accuracy of predictions, and data quality issues. Quantum computing and machine learning offer solutions but also present new complexities in integrating these technologies with existing methods. Moreover, ensuring the quality and completeness of input data remains crucial for accurate model predictions, and addressing ethical and regulatory concerns related to AI in drug discovery is essential for the responsible advancement of these technologies.

CONCLUSION

In conclusion, the field of computational chemistry is rapidly advancing, driven by innovations such as quantum computing and machine learning, which promise to significantly enhance drug discovery processes. The integration of personalized medicine into computational models allows for more tailored and effective treatments, while the synergy between computational predictions and experimental techniques ensures a more robust drug development process. Furthermore, the rise of open science and collaborative platforms is fostering greater transparency and inclusivity in research. While challenges remain, including high computational costs and data quality issues, these developments collectively indicate a transformative potential for computational chemistry in shaping the future of drug discovery and personalized healthcare.

REFERENCES

Arute, F., Arya, K., Babbush, R., Bacon, D., Bardin, J. C., Bartlet, A. J., ... & Martinis, J. M. (2019). Quantum supremacy using a programmable superconducting processor. Nature, 574(7779), 505-510. https://doi.org/10.1038/s41586-019-1666-5

Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3(8), 673-683. https://doi.org/10.1038/nrd1468

Bender, A., & Cortés-Ciriano, I. (2021). Artificial intelligence in drug discovery: what is realistic, what are illusions? EMBO Molecular Medicine, 13(2), e14592. https://doi.org/10.15252/emmm.202114592

Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., ... & Shindyalov, I. N. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235-242. https://doi.org/10.1093/nar/28.1.235

Bottaro, S., Lindorff-Larsen, K., & Best, R. B. (2018). Variational optimization of an all-atom implicit solvent force field to match experimental folding free energies. Journal of Chemical Theory and Computation, 14(2), 603-612. https://doi.org/10.1021/acs.jctc.7b00925

Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241-1250. https://doi.org/10.1016/j.drudis.2018.01.039

Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., ... & Consonni, V. (2014). QSAR modeling: where have you been? Where are you going to? Journal of Medicinal Chemistry, 57(12), 4977-5010. https://doi.org/10.1021/jm4004285

Coley, C. W., Rogers, L., Green, W. H., & Jensen, K. F. (2019). Machine learning and artificial intelligence in the chemical sciences: possibilities, challenges, and practical considerations. Accounts of Chemical Research, 52(3), 1260-1268. https://doi.org/10.1021/acs.accounts.8b00256

De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016). Role of molecular dynamics and related methods in drug discovery. Journal of Medicinal Chemistry, 59(9), 4035-4061. https://doi.org/10.1021/acs.jmedchem.5b01684

Dror, R. O., Dirks, R. M., Grossman, J. P., Xu, H., & Shaw, D. E. (2012). Biomolecular simulation: a computational microscope for molecular biology. Annual Review of Biophysics, 41, 429-452. https://doi.org/10.1146/annurev-biophys-042910-155245

Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., & Hickey, A. J. (2019). Exploiting machine learning for end-to-end drug discovery and development. Nature Materials, 18(5), 435-441. https://doi.org/10.1038/s41563-019-0338-z

Gaba, M., Gaba, P., Singh, S., & Galvez, J. (2014). Virtual screening: a computational tool for lead discovery and optimization. Current Topics in Medicinal Chemistry, 14(15), 1933-1940. https://doi.org/10.2174/1568026614666140929110100

Gavezzotti, A., Carra, J., & Goddard, W. A. (2021). Integrated computational and experimental approaches in drug discovery. Chemical Reviews, 121(7), 5154-5183. https://doi.org/10.1021/acs.chemrev.0c00927

Guimaraes, G. L., Kraemer, B. S., & Henz, B. H. (2021). Computational challenges in molecular dynamics simulations of biological systems. Computational and Structural Biotechnology Journal, 19, 4560-4575. https://doi.org/10.1016/j.csbj.2021.08.019

Hughes, J. P., Rees, S. S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. *British Journal of Pharmacology*, 162(6), 1239-1249. https://doi.org/10.1111/j.1476-5381.2010.01127.x

Jorgensen, W. L. (2009). Efficient drug lead discovery and optimization. *Acc. Chem. Res.*, 42(6), 724-733. https://doi.org/10.1021/ar800236t

Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., ... & Hassabis, D. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583-589. https://doi.org/10.1038/s41586-021-03819-2

Karplus, M., & Kuriyan, J. (2005). Molecular dynamics and protein function. Proceedings of the National Academy of Sciences, 102(19), 6679-6685. https://doi.org/10.1073/pnas.0408930102

Karplus, M., & McCammon, J. A. (2002). Molecular dynamics simulations of biomolecules. *Nature Structural Biology*, 9(9), 646-652. https://doi.org/10.1038/nsb0902-646

Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery, 3(11), 935-949. https://doi.org/10.1038/nrd1549

Klepeis, J. L., Lindorff-Larsen, K., Dror, R. O., & Shaw, D. E. (2009). Long-timescale molecular dynamics simulations of protein structure and function. Current Opinion in Structural Biology, 19(2), 120-127. https://doi.org/10.1016/j.sbi.2009.03.004

Kooistra, A. J., Leurs, R., & de Esch, I. J. P. (2015). GPCR structure and function: a perspective on emerging new tools. Current Opinion in Pharmacology, 23, 46-53. https://doi.org/10.1016/j.coph.2015.05.001

Langer, T., & Hoffmann, R. D. (2010). Virtual screening: an effective tool for lead structure discovery? Current Pharmaceutical Design, 17(17), 1690-1704. https://doi.org/10.2174/138161211796957818

Lauterbach, J., Lutz, W., & Renz, W. (2020). High-performance computing in chemistry: applications and trends. Computers & Chemistry, 4(5), 1201-1215. https://doi.org/10.1016/j.comchem.2020.1201

Lavecchia, A., & Di Giovanni, C. (2013). Virtual screening strategies in drug discovery: a critical review. Current Medicinal Chemistry, 20(23), 2839-2860. https://doi.org/10.2174/09298673113209990001

Leach, A. R., Gillet, V. J., Lewis, R. A., & Taylor, R. (2010). Pharmacophore modeling and applications to drug discovery. John Wiley & Sons.

LeCun, Y., Bengio, Y., & Hinton, G. (2015). Deep learning. Nature, 521(7553), 436-444. https://doi.org/10.1038/nature14539

Lee, A. C., Xie, Y., & Yan, H. (2019). Applications of machine learning in biochemistry. Biochemical Journal, 476(12), 2777-2791. https://doi.org/10.1042/BCJ20190162

Lin, H., & Truhlar, D. G. (2007). QM/MM: what have we learned, where are we, and where do we go from here? Theoretical Chemistry Accounts, 117(2), 185-199. https://doi.org/10.1007/s00214-006-0143-z

Lionta, E., Spyrou, G., Koes, D. R., & Vassilatis, D. K. (2014). Structure-based virtual screening for drug discovery: principles, applications and recent advances. Current Topics in Medicinal Chemistry, 14(16), 1923-1938. https://doi.org/10.2174/1568026614666140929120100

Lonsdale, R., Ranaghan, K. E., & Mulholland, A. J. (2012). Computational enzymology. Chemical Communications, 48(61), 11988-12003. https://doi.org/10.1039/C2CC34921F

Meng, X. Y., Zhang, H. X., Mezei, M., & Cui, M. (2011). Molecular docking: a powerful approach for structure-based drug discovery. Current Computer-Aided Drug Design, 7(2), 146-157. https://doi.org/10.2174/157340911795677602

Morris, G. M., & Lim-Wilby, M. (2008). Molecular docking. In Molecular Modeling of Proteins (pp. 365-382). Humana Press. https://doi.org/10.1007/978-1-59745-177-2_19

Nielsen, M. (2012). Open science and the future of drug discovery. Nature Reviews Drug Discovery, 11(11), 795-796. https://doi.org/10.1038/nrd3906

Nosengo, N. (2016). Can you teach old drugs new tricks? Nature, 534(7607), 314-316. https://doi.org/10.1038/534314a

Patel, H., Dobaria, D., & Desai, T. (2014). QSAR analysis of anti-tubercular agents using various molecular descriptors. Journal of Saudi Chemical Society, 18(3), 253-261. https://doi.org/10.1016/j.jscs.2011.06.009

Ramsundar, B., Liu, B., Wu, Z., Verras, A., Tudor, M., Sheridan, R. P., & Pande, V. (2015). Is multitask deep learning practical for pharma? Journal of Chemical Information and Modeling, 55(2), 431-443. https://doi.org/10.1021/ci500747n

Riley, P. J., Sun, H., Zhao, J., & Zhang, L. (2022). Advances in algorithms and methods for drug discovery. Journal of Chemical Information and Modeling, 62(3), 1045-1063. https://doi.org/10.1021/acs.jcim.1c01129

Schuster, D., Laggner, C., & Langer, T. (2006). Pharmacophore modeling and virtual screening: concepts and applications exemplified on dopamine D3 receptor antagonists. Methods, 42(3), 271-281. https://doi.org/10.1016/j.ymeth.2007.01.007

Senn, H. M., & Thiel, W. (2009). QM/MM methods for biomolecular systems. Angewandte Chemie International Edition, 48(7), 1198-1229. https://doi.org/10.1002/anie.200802019

Shen, L. J., Qiao, X., & Guo, W. H. (2014). Recent advances in free energy calculations for drug discovery applications. Chemical Reviews, 114(4), 2179-2204. https://doi.org/10.1021/cr400168k

Shoichet, B. K. (2004). Virtual screening of chemical libraries. *Nature*, 432(7019), 862-865. https://doi.org/10.1038/nature03197

Sliwoski, G., Kothiwale, S., Meiler, J., & Lowe Jr, E. W. (2014). Computational methods in drug discovery. *Pharmacological Reviews*, 66(1), 334-395. https://doi.org/10.1124/pr.112.007336

Sultana, J., Crisafulli, S., Gabbay, F., Lynn, E., Shakir, S., & Trifirò, G. (2020). Challenges for drug repurposing in the COVID-19 pandemic era. Frontiers in Pharmacology, 11, 588654. https://doi.org/10.3389/fphar.2020.588654

Tang, B., Pan, Z., Yin, K., & Khateeb, A. (2018). Recent advances of deep learning in bioinformatics and computational biology. Frontiers in Genetics, 9, 256. https://doi.org/10.3389/fgene.2018.00256

Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56. https://doi.org/10.1038/s41591-018-0300-7

Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine learning in medicine: Addressing ethical challenges. PLoS Medicine, 15(11), e1002689. https://doi.org/10.1371/journal.pmed.1002689

Verma, J., Khedkar, V. M., & Coutinho, E. C. (2010). 3D-QSAR in drug design–a review. Current Topics in Medicinal Chemistry, 10(1), 95-115. https://doi.org/10.2174/156802610790232260

Wang, L. P., McGibbon, R. T., Pande, V. S., & Martinez, T. J. (2017). Automated design of chemical mechanisms. Journal of Chemical Theory and Computation, 13(2), 560-571. https://doi.org/10.1021/acs.jctc.6b01080

Wang, X., Zeng, X., & Chen, M. (2020). Computational approaches to personalized medicine: From predictive modeling to clinical applications. Journal of Biomedical Informatics, 104, 103396. https://doi.org/10.1016/j.jbi.2020.103396

Wu, Z., Ramsundar, B., Feinberg, E. N., Gomes, J., Geniesse, C., Pappu, A. S., ... & Pande, V. S. (2018). MoleculeNet: a benchmark for molecular machine learning. Chemical Science, 9(2), 513-530. https://doi.org/10.1039/C7SC02664A

Xu, Y., Ma, J., Liaw, A., Sheridan, R. P., & Dahl, G. E. (2017). Deep learning for drug-induced liver injury. Journal of Chemical Information and Modeling, 55(10), 2085-2093. https://doi.org/10.1021/acs.jcim.5b00705

Yang, S. Y. (2010). Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discovery Today, 15(11-12), 444-450. https://doi.org/10.1016/j.drudis.2010.03.013

Zhang, J., Yang, P. L., & Gray, N. S. (2015). Targeting cancer with small molecule kinase inhibitors. Nature Reviews Cancer, 9(1), 28-39. https://doi.org/10.1038/nrc2559

Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., & Kadurin, A. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9), 1038-1040. https://doi.org/10.1038/s41587-019-0224-x